<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0103221774
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CREVAST 40 mg film-coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ROSUVASTATIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        183
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SPIMACO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C10AA07
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>CREVAST belongs to a group of medicines called statins. You have been prescribed CREVAST</p><p>because:</p><p>- You have a high cholesterol level. This means you are at risk from a heart attack or</p><p>stroke.You have been advised to take a statin, because changing your diet and taking more</p><p>exercise were not enough to correct your cholesterol levels. You should continue with your</p><p>cholestrol-lowering diet and exercise while you are taking CREVAST</p><p>Or</p><p>- You have other factors that increase your risk of having a heart attack, stroke or related</p><p>health problems.Heart attack, stroke and other problems can be caused by a disease called</p><p>atherosclerosis. Atherosclerosis is due to a build up of fatty deposits in your arteris.</p><p><strong>Why it is important to keep taking CREVAST</strong></p><p>&nbsp;</p><p>CREVAST is used to correct the levels of fatty substances in the blood called lipids, the most</p><p>common of which is cholesterol.</p><p>There are different types of cholesterol found in the blood &ndash; &ldquo;bad&rdquo; cholesterol (LDL-C) and</p><p>&ldquo;good&rdquo; cholesterol (HDL-C).</p><p>- CREVAST can reduce the &ldquo;bad&rdquo; cholesterol and increase the &ldquo;good&rdquo; cholesterol.</p><p>- It works by helping to block your body&rsquo;s production of &ldquo;bad&rdquo; cholesterol. It also</p><p>improves your body&rsquo;s ability to remove it from your blood.</p><p>For most people, high cholesterol does not affect the way they feel because it does not produce</p><p>any symptoms. However, if it is left untreated, fatty deposits can build up in the walls of your</p><p>blood vessels causing them to narrow.</p><p>Sometimes, these narrowed blood vessels can get blocked which can cut off the blood supply to</p><p>the heart or brain leading to a heart attack or a stroke. If you correct your cholesterol levels, you</p><p>can reduce your risk of having a heart attack or stroke.</p><p>You need to keep taking CREVAST, even if it has got your cholesterol to the right level, because</p><p>it prevents your cholesterol levels from creeping up again and causing build up of fatty deposits.</p><p>However, you should stop if your doctor tells you to do so, or if you have become pregnant.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take CREVAST:</strong></p><p>&bull; If you are allergic to rosuvastatin or any of the other ingredients of this medicine (listed in</p><p>section 6).</p><p>&bull; If you are pregnant or breast-feeding. If you become pregnant while taking CREVAST</p><p>stop taking it immediately and tell your doctor. Women should avoid becoming pregnant</p><p>while taking CREVAST by using suitable contraception.</p><p>&bull; If you have liver disease.</p><p>&bull; If you have severe kidney problems.</p><p>&bull; If you have repeated or unexplained muscle aches or pains.</p><p>&bull; If you take a drug called ciclosporin (used for example, after organ transplants).</p><p>If any of the above applies to you (or you are in doubt), please go back and see your doctor.</p><p><strong>In addition, do not take CREVAST 40 mg (the highest dose):</strong></p><p>&bull; If you have moderate kidney problems (if in doubt, please ask your doctor).</p><p>&bull; If your thyroid gland is not working properly.</p><p>&bull; If you have had any repeated or unexplained muscle aches or pains, a personal or family</p><p>history of muscle problems, or a previous history of muscle problems when taking other</p><p>cholesterol-lowering medicines.</p><p>&bull; If you regularly drink large amounts of alcohol.</p><p>&bull; If you are of Asian origin (Japanese, Chinese, Filipino, Vietnamese, Korean and Indian).</p><p>&bull; If you take other medicines called fibrates to lower your cholesterol.</p><p>If any of the above applies to you (or you are in doubt), please go back and see your doctor.</p><p><strong>Warnings and precautions</strong></p><p>&nbsp;</p><p>Talk to your doctor or pharmacist before taking CREVAST</p><p>&bull; If you have problems with your kidneys.</p><p>&bull; If you have problems with your liver.</p><p>&bull; If you have had repeated or unexplained muscle aches or pains, a personal or family</p><p>history of muscle problems, or a previous history of muscle problems when taking other</p><p>cholesterol-lowering medicines. Tell your doctor immediately if you have unexplained</p><p>muscle aches or pains especially if you feel unwell or have a fever.</p><p>&bull; If you regularly drink large amounts of alcohol.</p><p>&bull; If your thyroid gland is not working properly.</p><p>&bull; If you take other medicines called fibrates to lower your cholesterol. Please read this leaflet</p><p>carefully, even if you have taken other medicines for high cholesterol before.</p><p>&bull; If you take medicines used to fight the HIV infection e.g.lopinavir/ritonavir, please see</p><p>&ldquo;Other medicines and CREVAST&rdquo;.</p><p>&bull; If the patient is under 10 years old: CREVAST should not be given to children younger</p><p>than 10 years.</p><p>&bull; If the patient is below 18 years of age: The CREVAST 40 mg tablet is not suitable for use</p><p>in children and adolescents below 18 years of age.</p><p>&bull; If you are over 70 (as your doctor needs to choose the right start dose of CREVAST to suit</p><p>you).</p><p>&bull; If you are of Asian origin &ndash; that is Japanese, Chinese, Filipino, Vietnamese, Korean and</p><p>Indian. Your doctor needs to choose the right start dose of CREVAST to suit you.</p><p>If any of the above applies to you (or if you are not sure):</p><p>&bull; Do not take CREVAST 40 mg (the highest dose) and check with your doctor or pharmacist</p><p>before you actually start taking any dose of CREVAST.</p><p>In a small number of people, statins can affect the liver. This is identified by a simple test which</p><p>looks for increased levels of liver enzymes in the blood. For this reason, your doctor will usually</p><p>carry out this blood test (liver function test) before and during treatment with CREVAST.</p><p>While you are on this medicine your doctor will monitor you closely if you have diabetes or are</p><p>at risk of developing diabetes. You are likely to be at risk of developing diabetes if you have</p><p>high levels of sugars and fats in your blood, are overweight and have high blood pressure.</p><p>&nbsp;</p><p><strong>Other medicines and CREVAST</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other</p><p>medicines.</p><p>Tell your doctor if you are taking any of the following:</p><p>&bull; ciclosporin (used for example, after organ transplants),</p><p>&bull; warfarin (or any other drug used for thinning the blood),</p><p>&bull; fibrates (such as gemfibrozil, fenofibrate) or any other medicine used to lower cholesterol</p><p>(such as ezetimibe),</p><p>&bull; indigestion remedies (used to neutralise acid in your stomach),</p><p>&bull; erythromycin (an antibiotic),</p><p>&bull; an oral contraceptive (the pill),</p><p>&bull; hormone replacement therapy,</p><p>&bull; lopinavir/ritonavir (used to fight the HIV infection &ndash; please see &ldquo;Warnings and</p><p>precautions&rdquo;).</p><p>The effects of these medicines could be changed by CREVAST or they could change the effect</p><p>of CREVAST.</p><p><strong>CREVAST with food and drink</strong></p><p>You can take CREVAST with or without food.</p><p><strong>Pregnancy and breast-feeding</strong></p><p>Do not take CREVAST if you are pregnant or breast-feeding. If you become pregnant while</p><p>taking CREVAST stop taking it immediately and tell your doctor. Women should avoid</p><p>becoming pregnant while taking CREVAST by using suitable contraception.</p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p><p><strong>Driving and using machines</strong></p><p>Most people can drive a car and operate machinery while using CREVAST &ndash; it will not affect</p><p>their ability. However, some people feel dizzy during treatment with CREVAST. If you feel</p><p>dizzy, consult your doctor before attempting to drive or use machines.</p><p><strong>CREVAST contains lactose</strong></p><p>If you have been told by your doctor that you have an intolerance to some sugars (lactose or milk</p><p>sugar), contact your doctor before taking CREVAST.</p><p>For a full list of ingredients please see &ldquo;Contents of the pack and other information&rdquo; below.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or</p><p>pharmacist if you are not sure.</p><p><strong>Recommended dose in adults</strong></p><p><strong>If you are taking CREVAST for high cholesterol:</strong></p><p>Starting dose:</p><p>Your treatment with CREVAST must start with the 5 mg or the 10 mg dose, even if you have</p><p>taken a higher dose of a different statin before. The choice of your start dose will depend upon:</p><p>&bull; Your cholesterol level.</p><p>&bull; The level of risk you have of experiencing a heart attack or stroke.</p><p>&bull; Whether you have a factor that may make you more sensitive to possible side effects.</p><p>Please check with your doctor or pharmacist which start dose of CREVAST will best suit you.</p><p>Your doctor may decide to give you the lowest dose (5 mg) if:</p><p>&bull; You are of Asian origin (Japanese, Chinese, Filipino, Vietnamese, Korean and Indian).</p><p>&bull; You are over 70 years of age.</p><p>&bull; You have moderate kidney problems.</p><p>&bull; You are at risk of muscle aches and pains (myopathy).</p><p><strong>Increasing the dose and maximum daily dose</strong></p><p>Your doctor may decide to increase your dose. This is so that you are taking the amount of</p><p>CREVAST that is right for you. If you started with a 5 mg dose, your doctor may decide to</p><p>double this to 10 mg then 20 mg and then 40 mg if necessary. If you started on 10 mg, your</p><p>doctor may decide to double this to 20 mg and then 40 mg if necessary. There will be a gap of</p><p>four weeks between every dose adjustment.</p><p>The maximum daily dose of CREVAST is 40 mg. It is only for patients with high cholesterol</p><p>levels and a high risk of heart attacks or stroke whose cholesterol levels are not lowered enough</p><p>with 20 mg.</p><p><strong>If you are taking CREVAST to reduce your risk of having a heart attack, stroke or related</strong></p><p><strong>health problems:</strong></p><p>The recommended dose is 20 mg daily. However, your doctor may decide to use a lower dose if</p><p>you have any of the factors mentioned above.</p><p>Usual dose in children and adolescents aged 10-17 years</p><p>The usual start dose is 5mg. your doctor may increase your dose to find the right amount of</p><p>CREVAST for you. The maximum daily dose of CREVAST is 20 mg. Take your dose once a</p><p>day. CREVAST 40 mg tablet should not be used by children.</p><p>Taking your tablets</p><p>Swallow each tablet whole with a drink of water.</p><p>Take CREVAST once daily. You can take it at any time of the day.</p><p>Try to take your tablet at the same time every day to help you to remember it.</p><p>Regular cholesterol checks</p><p>It is important to go back to your doctor for regular cholesterol checks, to make sure your</p><p>cholesterol has reached and is staying at the correct level.</p><p>Your doctor may decide to increase your dose so that you are taking the amount of CREVAST</p><p>that is right for you.</p><p><strong>If you take more CREVAST than you should</strong></p><p>Contact your doctor or nearest hospital for advice.</p><p>If you go into hospital or receive treatment for another condition, tell the medical staff that</p><p>you&rsquo;re taking CREVAST.</p><p><strong>If you forget to take CREVAST</strong></p><p>Do not worry, just take your next scheduled dose at the correct time. Do not take a double dose</p><p>to make up for a forgotten tablet.</p><p><strong>If you stop taking CREVAST</strong></p><p>Talk to your doctor if you want to stop taking CREVAST. Your cholesterol levels might increase</p><p>again if you stop taking CREVAST.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>It is important that you are aware of what these side effects may be. They are usually mild and</p><p>disappear after a short time.</p><p><strong>Stop taking CREVAST and seek medical help immediately</strong> if you have any of the following</p><p>allergic reactions:</p><p>&bull; Difficulty in breathing, with or without swelling of the face, lips, tongue and/or throat</p><p>&bull; Swelling of the face, lips, tongue and/or throat, which may cause difficulty in swallowing</p><p>&bull; Severe itching of the skin (with raised lumps).</p><p><strong>Also, stop taking CREVAST and talk to your doctor immediately if you have any unusual</strong></p><p><strong>aches or pains </strong>in your muscles which go on for longer than you might expect. As with other</p><p>statins, a very small number of people have experienced unpleasant muscle effects and rarely</p><p>these have gone on to become a potentially life threatening muscle damage known as</p><p>rhabdomyolysis.</p><p><strong>Common possible side effects (affects 1 to 10 users in 100):</strong></p><p>&bull; Headache</p><p>&bull; Stomach pain</p><p>&bull; Constipation</p><p>&bull; Feeling sick</p><p>&bull; Muscle pain</p><p>&bull; Feeling weak</p><p>&bull; Dizziness</p><p>&bull; An increase in the amount of protein in the urine &ndash; this usually returns to normal on its own</p><p>without having to stop taking your CREVAST tablets (only CREVAST 40 mg).</p><p>&bull; Diabetes. This is more likely if you have high levels of sugars and fats in your blood, are</p><p>overweight and have high blood pressure. Your doctor will monitor you while you are</p><p>taking this medicine.</p><p><strong>Uncommon possible side effects (affects 1 to 10 users in 1,000):</strong></p><p>&bull; Rash, itching or other skin reactions</p><p>&bull; An increase in the amount of protein in the urine &ndash; this usually returns to normal on its own</p><p>without having to stop taking your CREVAST tablets (only CREVAST 5 mg, 10 mg and</p><p>20 mg).</p><p><strong>Rare possible side effects (affects 1 to 10 users in 10,000):</strong></p><p>&nbsp;</p><p>Severe allergic reaction &ndash; signs include swelling of the face, lips, tongue and/or throat,</p><p>difficulty in swallowing and breathing, a severe itching of the skin (with raised lumps). If</p><p>you think you are having an allergic reaction, then stop taking CREVAST and seek</p><p>medical help immediately.</p><p>&bull; Muscle damage &ndash;as a precaution, stop taking CREVAST and talk to your doctor</p><p>immediately if you have any unusual aches or pains in your muscles which go on for</p><p>longer than expected.</p><p>&bull; A severe stomach pain (inflamed pancreas).</p><p>&bull; Increase in liver enzymes in the blood.</p><p>&bull; Reduction in platelets in the blood.</p><p><strong>Very rare possible side effects (affects less than 1 user in 10,000):</strong></p><p>&bull; Jaundice (yellowing of the skin and eyes)</p><p>&bull; Hepatitis (an inflamed liver)</p><p>&bull; Traces of blood in your urine</p><p>&bull; Damage to the nerves of your legs and arms (such as numbness)</p><p>&bull; Joint pain</p><p>&bull; Memory loss</p><p>&bull; Gynecomastia (breast enlargement in men and women)</p><p><strong>Side effects of unknown frequency (frequency cannot be estimated from the available data)</strong></p><p><strong>may include</strong>:</p><p>&bull; Diarrhoea (loose stools)</p><p>&bull; Stevens-Johnson syndrome (serious blistering condition of the skin, mouth, eyes and</p><p>genitals)</p><p>&bull; Cough</p><p>&bull; Shortness of breath</p><p>&bull; Oedema (swelling)</p><p>&bull; Sleep disturbances, including insomnia and nightmares</p><p>&bull; Sexual difficulties</p><p>&bull; Depression</p><p>&bull; Breathing problems, including persistent cough and/or shortness of breath</p><p>&bull; Tendon injury</p><p>If you get any side effects, talk to your doctor or pharmacist.This includes any side effects not</p><p>listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the sight and reach of children.</p><p>Do not store above 30&ordm; C.</p><p>Do not use this medicine after the expiry date which is stated on the box/blisters/label after EXP.</p><p>The expiry date refers to the last day of that month.</p><p>This medicinal product does not require any special storage conditions.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how</p><p>to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- The active substance in CREVAST is rosuvastatin. CREVAST film-coated tablets contain</p><p>rosuvastatin calcium equivalent to 5 mg, 10 mg, 20 mg or 40 mg of rosuvastatin.</p><p>- The other ingredients are:</p><p>&bull; tablet core: microcrystalline cellulose, crospovidone type A, calcium hydrogen phosphate</p><p>dihydrate, lactose monohydrate, magnesium stearat.</p><p>&bull; tablet coat: hypromellose, titanium dioxide (E171), lactose monohydrate, macrogol 3350,</p><p>triacetin.</p><p>CREVAST 10 mg, 20 mg and 40 mg film-coated tablets also contain carmine (E120).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                CREVAST comes in four tablet strengths:
CREVAST 5 mg film-coated tablets are white, round, biconvex, film-coated tablets engraved
with “66” on one side and plain on the other side.
CREVAST 10 mg film-coated tablets are pink, round, biconvex, film-coated tablets engraved
with “67” on one side and plain on the other side.
CREVAST 20 mg film-coated tablets are pink, round, biconvex, film-coated tablets engraved
with “107” on one side and plain on the other side.
CREVAST 40 mg film-coated tablets are pink, round, biconvex, film-coated tablets engraved
with “108” on one side and plain on the other side.
Crevast comes in blister packs containing 30 tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>SPIMACO</p><p>Al-Qassim pharmaceutical plant</p><p>Saudi Pharmaceutical Industries &amp;</p><p>Medical Appliance Corporation</p><p>Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was revised in July 2017.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>كريفاست ينتمي إلى مجموعة من الأدوية تعرف باسم ستاتين. وقد تم وصف كريفاست لك بسبب:</p><ul><li>ارتفاع مستوى الكوليسترول لديك بالدم. مما يعني تعرضك لخطر الاصابة بأزمة قلبية أو سكته دماغية. لذلك، تم إرشادك إلى تناول ستاتين حيث أن تغييرك لنظامك الغذائي وقيامك بالتمارين الرياضية غير كافِ لتعديل مستوى الكوليسترول لديك بالدم. لذلك يجب عليك الاستمرار في الالتزام بالحمية الغذائية التي تقلل من مستوى الكوليسترول لالدم والقيام بالتمارين الرياضية أثناء تناول أقراص كريفاست.</li></ul><p>&nbsp;</p><p>أو</p><ul><li>لديك عوامل أخرى تزيد من خطورة تعرضك للإصابة بأزمة أو سكته دماغية أو مشاكل صحية أخرى متعلقة بهما. الأزمات القلبية والسكته الدماغية وغيرها من المشاكل يمكن ان يكون سببها مرض يسمى تصلب الشرايين. وتصلب الشرايين يرجع إلى تراكم الترسبات الدهنية في الشرايين.</li></ul><p>&nbsp;</p><p>لماذا يكون من الضروري استمرارك في تناول كريفاست</p><p>يستخدم كريفاست لتصحيح مستويات المواد الدهنية في الدم والتي تسمى الدهون ، ومن أكثرها شيوعاً هو الكوليسترول. هناك أنواع مختلفة من الكوليسترول الموجود في الدم - الكوليسترول &rdquo; الضار&ldquo; ( LDL-C) الكوليسترول &rdquo; الجيد&ldquo; ( HDL-C)</p><ul><li>كريفاست يمكنه أن يعمل على إنقاص الكوليسترول &rdquo; الضار&ldquo; وزيادة الكوليسترول &rdquo; الجيد&ldquo;.</li></ul><p>&nbsp;</p><ul><li>وهو يعمل عن طريق المساعدة على منع إنتاج الجسم من الكوليسترول &rdquo; الضار&ldquo;. كما انه يحسن قدرة الجسم على إزالته من الدم.</li></ul><p>&nbsp;</p><p>بالنسبة لمعظم الناس ، ارتفاع الكوليسترول لا يؤثر على الطريقة التي يشعرون بها لأنه لا يسبب أي اعراض. ومع ذلك، إذا تركت الحاله بدون علاج، يمكن للترسبات الدهنية أن تتراكم في جدران الأوعية الدموية مما يسبب لها التضيق.</p><p>أحياناً يمكن لهذه الاوعية الدموية التي تضيقت أن تتعرض إلى الانسداد مما يؤدي إلى قطع إمدادات الدم إلى القلب أو الدماغ مما يؤدي إلى أزمة قلبية أو سكته دماغية. إذا كنت تقوم بتصحيح مستويات الكوليسترول في الدم لديك، يمكنك تقليل خطر الإاصبة بأزمة قلبية أو سكته دماغيه.</p><p>&nbsp;</p><p>أنت بحاجه إلى الحفاظ على تناول كريفاست، حتى إذا وصل مستوى الكوليسترول لديك بالدم إلى المستوى الصحيح، وذلك لأن كريفاست يمنع مستوى الكوليسترول لديك من الارتفاع مره اخرى والتسبب في تراكم الترسبات الدهنية. ومع ذلك، يجب أن تتوقف إذا اخبرك طبيبك المعالج بذلك، أو إذا كنت قد أصبحت حاملاً.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تقم بتناول كريفاست في الحالات الاتيه:</p><p>اذا كنت تعاني من فرط التحسس تجاه مادة روزفاستاتين أو اي من المكونات الأخرى لهذا الدواء ( والمذكوره في الفقرة ٦ )</p><p>&nbsp;</p><ul><li>إذا كنت حاملاً آو ترضعين طفلك طبيعياً. إذا أصبحتِ حاملاً أثناء تناول كريفاست، توقفي عن تناوله فوراً وأخبري طبيبك المعالج بذلك. حيث ينبغي على السيدات تجنب حدوث الحمل أثناء تناول كريفاست عبر استخدام وسيلة مناسبة لمنع الحمل.</li><li>إذا كنت مصاباً بمرض بالكبد.</li><li>إذا كنت تعاني من مشاكل حادة بالكلى.</li><li>إذا كنت تتعرض لأوجاع أو الام متكررة أو غير مبررة بالعضلات.</li><li>إذا كنت تتناول دواء يسمى سيكلوسبورين ( والذي يستخدم على سبيل المثال بعد زراعة الآعضاء)</li></ul><p>في حالج انطباق أي من الحالات المذكوره أعلاه عليك ( أو غي حالة عدم تأكدك)، فضلاً أخبر طبيبك المعالج.</p><p>التحذيرات والاحتياطات</p><p>تحدث الى طبيبك المعالج أو الصيدلي قبل البدء في تناول كريفاست في الحالات الاتيه:</p><ul><li>إذا كنت تعاني من مشاكل بالكلى.</li><li>أذا كنت تعاني من مشاكل بالكبد.</li><li>إذا كنت تتعرض لأوجاع أو الام متكررة أو غير مبررة بالعضلات، أو إذا كان لديك تاريخ شخصي أو عائلي من مشاكل بالعضلات أو لديك تاريخ مسبق من مشاكل بالعضلات عند تناولك لأدوية لخفض مستوى الكوليسترول.</li></ul><p>&nbsp;</p><p>أخبر طبيبك المعالج فوراً إذا تعرضت لآلام أو أوجاع غير مبررة بالعضلات خصوصاً إذا كنت تشعر بتوعك أو أصبت بحمى.</p><ul><li>إذا كنت تتناول كميات كبيرة من الكحول بانتظام.</li><li>إذا كانت الغدة الدرقية لديك لا تعمل بشكل سليم.</li><li>إذا كنت تتناول أدوية أخرى تسمى الفايبريت لخفض متسوى الكوليسترول . يرجى قراءة هذه النشرة بعناية، حتى لو كنت قد تناولت مسبقاً أي أدوية أخرى لارتفاع الكوليتسرول في الدم.</li><li>إذا كنت تتناول الأدوية المستخدمه لمكافحة عدوى فيروس نقص المناعة البشرية مثل لوبينافير\ ريتونافير، فضلاًانظر فقرة &rdquo; تناول كريفاست مع أدوية أخرى&ldquo;</li><li>إذا كان المريض أقل في العمر من ١٠ سنوات: حيث يحظر إعطاء كريفاست للأطفال الأقل في العمر من ١٠ سنوات.</li><li>إذا كان المريض أقل في العمر من ١٨ سنة: حيث يحظر إعطاء كريفاست ٤٠ ملجم&nbsp; للأطفال والمراهقين الأقل في العمر من ١٨ سنة.</li><li>إذا كنت تجاوزت ٧٠ سنة من العمر ( حيث ينبغي على طبيبك المعالج تحديد جرعة البداية المناسبة لك من كريفاست).</li><li>إذا كنت من اصل اسيوي - وهي اليابانية والصينية والفلبينية والفيتنامية والكورية والهندية. حيث ينبغي على طبيبك المعالج تحديد جرعة البداية المناسبة لك من كريفاست.</li></ul><p>في حالة انطباق أي من الحالات المذكوره أعلاه عليك ( أو إذا كنت غير متأكداً):</p><ul><li>لا تقم بتناول كريفاست ٤٠ ملجم ( وهي الجرعة الأعلى) وتحقق من خلال طبيبك المعالج أو الصيدلي قبل البدء في تناول أي جرعة من كريفاست.</li></ul><p>قد يؤثر تناول ستاتين على الكبد في عدد قليل من الناس. والذي يستدل عليه من خلال اختبار بسيط للدم لفحص الزيادة في مستوى إنزيمات الكبد. لذلك، سيقوم طبيبك المعالج بإجراء هذا الفحص بشكل منتظم ( فحص وظائف الكبد) قبل وأثناء تناول كريفاست.</p><p>أثناء خضوعك لتناول هذا الدواء سيقوم طبيبك المعالج بفحصك بعناية اذا كنت مصاباً بمرض السكر أو معرض لخطر الإصابة بمرض السكر. من المحتمل أن تكون معرضاً لخطر الإصابة بمرض السكر اذا كان لديك ارتفاع في مستويات السكر والدهون في الدم و إذا كنت زائداً في الوزن وإذا كنت تعاني من ارتفاع ضغط الدم.</p><p>تناول كريفاست مع ادوية اخرى</p><p>أخبر طبيبك المعالج أو الصيدلي إذا كنت تتناول حالياً او مؤخراً أي أدوية أخرى.</p><p>أخبر طبيبك المعالج إذا كنت تتناول أي من الأدوية الاتيه:</p><ul><li>سيكلوسبورين ( والذي يستخدم على سبيل المثال بعد زراعة الاعضاء)</li><li>وارفارين ( أو أي أدوية أخرى تستخدم لتمييع الدم )</li><li>الفايبريت ( مثل جيمفيبروزيل ، فينوفايبريت) أو أي أدوية أخرى تعمل على انقاص متسوى الكوليسترول بالدم ( مثل إيزيتيميب)</li><li>أدوية عسر الهضم ( التي تستخدم لإبطال مفعول الحمض الموجود في المعدة)</li><li>أريثروميسين ( مضاد حيوي)</li><li>أقراص منع الحمل ( عن طريق الفم )</li><li>العلاج باستخدام الهرمونات التعويضيه</li><li>لوبينافير\ريتونافير ( والتي تستخدم لمكافحة عدوى فيروس نقص المناعة البشرية - فضلاً انظر فقرة &rdquo; التحذيرات والاحتياطات&ldquo;)</li></ul><p>قد يتغير نفعول تلك الادوية بواسطة كريفاست أو قد تغير تلك الأدوية من مفعول كريفاست.</p><p>تناول كريفاست مع الطعام والشراب</p><p>يمكنك تناول كريفاست مع الطعام أو بدونه</p><p>الحمل والرضاعة</p><p>يجب عدم تناول كريفاست في حالة الحمل أو الرضاعة. إذا أصبحت حاملاً أثناء تناول كريفاست ، توقفي عن تناوله فوراً&nbsp; وأخبري طبيبك المعالج بذلك. يجب على السيدات تجنب حدوث الحمل أثناء تناول كريفاست عبر استخدام وسيلة مناسبة لمنع الحمل.</p><p>اسالي طبيبك المعالج أو الصيدلي للمشورة قبل البدء في تناول أي أدوية.</p><p>القيادة واستخدام الالات</p><p>معظم الناس يمكنهم قيادة السياره وتشغيل الالات أثناء العلاج بكريفاست - حيث لن يؤثر على قدرتهم على ذلك. ومع ذلك قد يشعر بعض الناس بدوخه أثناء العلاج بكريفاست. لذلك، إذا تعرضت للشعور بدوخة، استشر طبيبك المعالج قبل محاولة القيادة أو استخدام الالات.</p><p>كريفاست يحتوي على اللاكتوز</p><p>إذا تم إخبارك من قبل طبيبك المعالج بعدم تحملك لبعض أنواع السكر مثل ( اللاكتوز أو سكر اللبن )، تواصل مع طبيبك المعالج قبل البدء بتناول كريفاست.</p><p>لمعرفة جميع مكونات أقراص كريفاست فضلاً انظر الفقرة &rdquo; محتويات العبوة ومعلومات أخرى&ldquo; أدناه.</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>قم دائماً بتناول هذا الدواء تماماً كما أخبرك طبيبك المعالج. تحقق من خلال طبيبك المعالج أو الصيدلي في حالة عدم تأكدك.</p><p>الجرعة الموصى بها للبالغين</p><p>إذا كنت تتناول كريفاست لارتفاع&nbsp; مستوى الكوليسترول:</p><ul><li>مستوى الكوليسترول لديك بالدم.</li><li>مدى خطورة تعرضك للإصابة بأزمة قلبية أو سكتة دماغية.</li><li>إذا لديك أي من العوامل التي تزيد من حساسيتك تجاه الأعراض الجانبية المحتملة لهذا الدواء.</li></ul><p>فضلاً تأكد من طبيبك المعالج أو الصيدلي بشأن جرعة البداية المناسبة لحالتك من كريفاست.</p><p>قد يصف لك طبيبك المعالج أقل جرعة ( ٥ ملجم) في الحالات الاتية:</p><ul><li>إذا كنت من اصل آصل اسيوي ( وهي اليابانية والصينية والفلبينية والفيتنامية والكورية والهندية ).</li><li>إذا كنت تجاوزت ٧٠ سنة من العمر.</li><li>إذا كنت تعاني من مشاكل متوسطة بالكلى.</li><li>إذا كنت معرضاً لخطر الإصابة بأوجاع وآلام العضلات ( اعتلال عضلي).</li></ul><p>زيادة الجرعة والحد الأقصى للجرعة اليومية</p><p>قد يقرر طبيبك المعالج زيادة الجرعة الخاصة بك. بحيث يمكنك تناول الجرعة الصحيحة المناسبة لحالتك من كريفاست. إذا بدأت بتناول جرعة ٥ ملجم ، قد يقوم طبيبك المعالج بمضاعفة الجرعة إلى ١٠ ملجم ثم إلى ٢٠ ملجم وبعدها إلى ٤٠ ملجم إذا لزم الامر. وسوف يكون هناك فترة أربعة أسابيع بين كل تغيير في الجرعة. الحد الاقصى للجرعة اليومية من كريفاست هو ٤٠ ملجم. وهي خاصة فقط بالمرضى المصابين بارتفاع مستوى الكوليسترول بالدم بشكل كافٍ بواسطة استخدام كريفاست ٢٠ ملجم.</p><p>&nbsp;</p><p>إذا كنت تتناول كريفاست للحد من خطورة إصابتك بأزمة قلبية أو سكته دماغية أو مشاكل صحية أخرى متعلقة بهما:</p><p>تكون الجرعة الموصى بها هي ٢٠ ملجم يومياً. ومع ذلك ، قد يلجأ طبيبك المعالج إلى تقليل الجرعة إذا كان لديك أي من العوامل المذكورة أعلاه.</p><p>الجرعة المعتادة للأطفال والمراهقين في سن ١٠-١٧ سنة من العمر</p><p>جرعة البداية المعتادة هي ٥ ملجم. وقد يلجأ الطبيب إلى زيادة الجرعة من كريفاست للحصول على الجرعة المناسبة لحالتك. الحد الأقصى للجرعة اليومية من كريفاست هو ٢٠ ملجم. قم بتناول الجرعة مرة واحدة يومياً. ينبغي عدم استخدام كريفاست ٤٠ ملجم للأطفال.</p><p>كيفية تناول الأقراص</p><p>قم بابتلاع القرص كاملاً مع كوب من الماء. قم بتناول كريفاست مرة واحدة يومياً. يمكنك تناول القرص في اي وقت من اليوم . احرص على&nbsp; محاولة تناول القرص في نفس الوقت من كل يوم لتساعد نفسك على تذكر الدواء.</p><p>فحص مستوى الكوليسترول بانتظام</p><p>من الضروري أن تعود إلى طبيبك المعالج لإجراء فحوص لمستوى الكوليسترول بالدم بشكل منتظم للتأكد من وصول مستوى الكوليسترول إلى المستوى الصحيح والبقاء علية.</p><p>حيث قد يلجأ طبيبك المعالج إلى زيادة الجرعة الخاصة بك من كريفاست لتتمكن من تناول الجرعة المناسبة لحالتك.</p><p>في حالة تناولك كريفاست أكثر مما ينبغي</p><p>تواصل مع طبيبك المعالج أو أقرب مستشفى للمشورة.</p><p>إذا توجهت إلى المستشفى أو تلقيت أي علاج آخر لإي سبب، أخبر الفريق الطبي بالمستشفى بأنك تتناول كريفاست.</p><p>في حالة نسيان تناول كريفاست</p><p>لا تقلق، فقط قم بتناول الجرعة التالية في وقتها الصحيح. لا تقم بمضاعفة الجرعة لتعويض الجرعة المنسية.</p><p>في حالة التوقف عن تناول كريفاست</p><p>تحدث إلى طبيبك المعالج إذا كنت ترغب في التوقف عن تناول كريفاست. حيث قد يزداد مستوى الكوليسترول لديك بالدم مره أخرى إذا توقفت عن تناول كريفاست.</p><p>إذا كانت لديك أي أسئلة إضافية بشأن استخدام هذا الدواء، اسال طبيبك المعالج أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية قد يسبب هذا الدواء أعراضاً جانبية، وإن لم تكن تحدث لكل من يتناول هذا الدواء.</p><p>من الضروري لك معرفة ما هي تلك الأعراض الجانبية المحتمل حدوثها. والتي عادةً تكون خفيفة وتزول بعد وقت قصير.</p><p>توقف عن تناول كريفاست وابحث عن المساعدة الطبية فوراً في حالة تعرضك لأي من التفاعلات التحسسية الآتية:</p><ul><li>صعوبة في التنفس ، مع أو بدون تورم في الوجه والشفتين واللسان و\ أو الحلق.</li><li>تورم في الوجه والشفتين واللسان و \ أو الحلق ، والتي قد تسبب صعوبة في البلع.</li><li>حكة شديدة في الجلد ( مع وجود تورم )</li></ul><p>ايضاً توقف عن تناول كريفاست وتحدث إلى طبيبك المعالج في الحال إذا تعرضت لأي أوجاع أو آلام غير معتادة في العضلات والتي قد تستمر لوقت أطول مما تتوقع. كما هو الحال مع غيرها من أدوية الستاتين قد تعرض عدد قليل جداً من الناس إلى تأثيرات ضارة على العضلات والتي نادرً ما تؤدي&nbsp; إلى حالة تلف بالعضلات قد تهدد الحياة والتي تعرف باسم انحلال الربيدات.</p><p>أعراض جانبية شائعة ( والتي تصيب من ١ إلى ١٠ من كل ١٠٠ مستخدم لهذا الدواء):</p><ul><li>صداع</li><li>الم بالبطن</li><li>إمساك</li><li>شعور بالاعياء</li><li>ألم بالعضلات</li><li>شعور بالضعف</li><li>دوخة</li><li>زيادة كمية البروتين في البول ( فقط في حالة كريفاست ٤٠ ملجم ) - والتي عادةً تعود إلى المستوى الطبيعي&nbsp; بدون الحاجة إلى التوقف عن تناول أقراص كريفاست.</li><li>مرض السكر. والذث تزيد احتمالية الإصابة في حالة ارتفاع مستوى السكريات والدهون بالدم وزيادة الوزن وارتفاع ضغط الدم. لذلك، سيقوم طبيبك المعالج بفحصك أثناء تناول هذا الدواء.</li></ul><p>&nbsp;</p><p>أعراض جانبية غير شائعة ( والتي تصيب من ١ إلى ١٠ من كل ١٠٠٠ مستخدم لهذا الدواء):</p><ul><li>طفح جلدي أو حكة أو تفاعلات جلدية أخرى.</li><li>زيادة كمية البروتين في البول ( فقط في حالة كريفاست ٥ ملجم ، ١٠ ملجم ، ٢٠ ملجم ) - والتي عادةً تعود إلى المستوى الطبيعي بدون الحاجة إلى التوقف عن تناول أقراص كريفاست.</li></ul><p>&nbsp;</p><p>أعراض جانبية نادرة ( والتي تصيب من ١ إلى ١٠ من كل ١٠٠٠٠ مستخدم لهذا الدواء):</p><ul><li>تفاعلات تحسسية حادة - وأعراضها هي تورم الوجة ، الشفتين ، اللسان و \ أو الحلق ، صعوبة في البلع والتنفس ، وحكة شديدة بالجلد ( مع وجود تورم ). إذا كنت تعتقد أنك تعاني من تفاعل تحسسي ، توقف فوراً عن تناول كريفاست وابحث عن المساعدة الطبية في الحال.</li><li>تلف بالعضلات - كنوع من الاحتياط ، توقف عن تناول كريفاست وتحدث إلى طبيبك المعالج فوراً إذا تعرضت لأي اوجاع أو آلام غير معتادة بالعضلات والتي قد تستمر لوقت أطول مما تتوقع.</li><li>ألم شديد بالبطن ( التهاب البنكرياس)</li><li>أرتفاع مستوى إنزيمات الكبد بالدم.</li><li>انخفاض الصفائح الدموية بالدم.</li></ul><p>&nbsp;</p><p>أعراض جانبية نادرة جداً ( والتي تصيب أقل من ١ من كل ١٠٠٠٠ مستخدم لهذا الدواء):</p><ul><li>اليرقان ( اصفرار الجلد واصفرار بياض العينين )</li><li>التهاب الكبد</li><li>اثار وجود دم بالبول</li><li>تلف بأعصاب الساقين والذراعين ( مثل التنميل )</li><li>ألم بالمفاصل</li><li>فقدان الذاكرة</li><li>التثدي ( تضخم الثدي لدى الرجال والسيدات ).</li></ul><p>&nbsp;</p><p>أعراض جانبية غير معلومة المعدل ( معدل تكرار حدوثها لا يمكن أن يستدل عليه من المعلومات المتاحة) وقد تشمل:</p><ul><li>إسهال</li><li>متلازمة ستيفنز جونسون ( حالة ظهور خطيرة في الجلد والفم والعينين والأعضاء التناسلية )</li><li>سعال</li><li>ضيق في التنفس</li><li>وذمة ( تورم )</li><li>اضطرابات النوم وتشمل الارق والكوابيس</li><li>اضطرابات جنسية</li><li>اكتئاب</li><li>مشاكل في التنفس، وتشمل السعال المستمر و \ أو ضيق في التنفس.</li><li>إصابة في الأوتار.</li></ul><p>إذا تعرضت لحدوث أي أعراض جانبية ، تحدث ألى طبيبك المعالج أو الصيدلي. ويشمل ذلك اي أعراض جانبية لم يتم ذكرها في هذة النشرة.</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ بعيداً عن نظر و متناول الأطفال.</p><p>لا يحفظ في درجة حرارة أعلى من ٣٠ درجة مئوية</p><p>لا تستخدم هذا الدواء بعد انتهاء تاريخ الصلاحية المذكورة على العبوة \ الشريط \ الملصق بعد كلمة EXP. علماً بان تاريخ الصلاحية يشير إلى اخر يوم بالشهر المذكور.</p><p>هذا الدواء لا يتطلب أي شروط خاصة للتخزين.</p><p>لا تتخلص من الأدوية عبر مياة الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. فسوف تساعد هذه التدابير في حماية البيئية.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><ul><li>المادة الفعالة في أقراص كريفاست هي روزوفاستاتين. أقراص كريفاست المغطاة بطبقة رقيقة تحتوي على روزوفاستاتين</li><li>مكونات أخرى وهي:</li></ul><ul><li>لب القرص : سيليولوز دقيق التبلور ، كروسبوفيدون نوع A ، كالسيوم هيدروجين فوسفات ثنائي الهيدرات ، لاكتوز أحادى التمية ، ستيارات المغنسيوم.</li><li>غطاء القرص: هيبروميللوز ، ثاني أكسيد التيتانيوم ( E171) ، لاكتوز أحادى التمية ، ماكروجول 3350 ثلاثي الأستين.</li></ul><p>أقراص كريفاست المغطاة بطبقة رقيقة ١٠ ملجم و ٢٠ ملجم و ٤٠ ملجم أيضا تحتوي علي كارمين ( E120).</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>تتوفر أقراص كريفاست في أربعة تركيزات: كريفاست 5 ملجم أقراص مغطاة بطبقة رقيقة وهي اقراص بيضاء ، مستديرة ، ثنائية التحدب ، مغطاة بطبقة رقيقة محفورة على احد جانبيها &rdquo;66&ldquo; وعادية علي الجانب الاخر. كريفاست 10 ملجم أقراص مغطاة بطبقة رقيقة وهي اقراص وردية اللون ، مستديرة ، ثنائية التحدب ، مغطاة بطبقة رقيقة محفورة على احد جانبيها &rdquo;67&ldquo; وعادية علي الجانب الاخر. كريفاست 20 ملجم أقراص مغطاة بطبقة رقيقة وهي اقراص وردية اللون ، مستديرة ، ثنائية التحدب ، مغطاة بطبقة رقيقة محفورة على احد جانبيها &rdquo;107&ldquo; وعادية علي الجانب الاخر. كريفاست 40 ملجم أقراص مغطاة بطبقة رقيقة وهي اقراص وردية اللون ، مستديرة ، ثنائية التحدب ، مغطاة بطبقة رقيقة محفورة على احد جانبيها &rdquo;108&ldquo; وعادية علي الجانب الاخر. تتوفر أقراص كريفاست في شرائط داخل عبوات تحتوي على 30 قرص.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>الدوائية</p><p>مصنع الادوية بالقصيم</p><p>الشركة السعودية للصناعات الدوائية والمستلزمات الطبية</p><p>المملكة العربية السعودية</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            يوليو 2017
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                CREVAST 5 mg film-coated tablets.
CREVAST 10 mg film-coated tablets.
CREVAST 20 mg film-coated tablets.
CREVAST 40 mg film-coated tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 5 mg rosuvastatin (as rosuvastatin calcium).
Each tablet contains 10 mg rosuvastatin (as rosuvastatin calcium).
Each tablet contains 20 mg rosuvastatin (as rosuvastatin calcium).
Each tablet contains 40 mg rosuvastatin (as rosuvastatin calcium).
Excipients with known effect:
Each 5 mg tablet contains 32,15 mg lactose monohydrate.
Each 10 mg tablet contains 64,30 mg lactose monohydrate.
Each 20 mg tablet contains 128,60 mg lactose monohydrate.
Each 40 mg tablet contains 257,21 mg lactose monohydrate.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.
CREVAST 5 mg film-coated tablets are white, round, biconvex, film-coated tablets engraved
with “66” on one side and plain on the other side.
CREVAST 10 mg film-coated tablets are pink, round, biconvex, film-coated tablets engraved
with “67” on one side and plain on the other side.
CREVAST 20 mg film-coated tablets are pink, round, biconvex, film-coated tablets engraved
with “107” on one side and plain on the other side.
CREVAST 40 mg film-coated tablets are pink, round, biconvex, film-coated tablets engraved
with “108” on one side and plain on the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Treatment of hypercholesterolemia</strong></p><p>CREVAST is indicated in adults, adolescents and children aged 10 years or older with&nbsp;primary hypercholesterolemia (type IIa including heterozygous familial&nbsp;hypercholesterolemia) or mixed dyslipidaemia (type IIb) as an adjunct to diet when response&nbsp;to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is&nbsp;inadequate.&nbsp;CREVAST is indicated in homozygous familial hypercholesterolemia as an adjunct to diet&nbsp;and other lipid lowering treatments (e.g. LDL apheresis) or if such treatments are not&nbsp;appropriate.&nbsp;Prevention of Cardiovascular Events&nbsp;CREVAST is indicated in prevention of major cardiovascular events in patients who are &nbsp;estimated to have a high risk for a first cardiovascular event (see section 5.1), as an adjunct to&nbsp;correction of other risk factors.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>Before treatment initiation the patient should be placed on a standard cholesterol-lowering&nbsp;diet that should continue during treatment. The dose should be individualised according to the&nbsp;goal of therapy and patient response, using current consensus guidelines.</p><p><strong>Treatment of hypercholesterolemia</strong></p><p>The recommended start dose is 5 or 10 mg orally once daily in both statin na&iuml;ve or patients&nbsp;switched from another HMG CoA reductase inhibitor. The choice of start dose should take&nbsp;into account the individual patient&rsquo;s cholesterol level and future cardiovascular risk as well as&nbsp;the potential risk for adverse reactions (see below). &nbsp;dose adjustment to the next dose level&nbsp;can be made after 4 weeks, if necessary (see section 5.1). In light of the increased reporting&nbsp;rate of adverse reactions with the 40 mg dose compared to lower doses (see section 4.8), a&nbsp;final titration to the maximum dose of 40 mg should only be considered in patients with&nbsp;severe hypercholesterolemia&nbsp;at high cardiovascular risk (in particular those with familial&nbsp;hypercholesterolemia), who do not achieve their treatment goal on 20 mg, and in whom&nbsp;routine follow-up&nbsp;will be performed (see section 4.4). Specialist supervision is recommended&nbsp;when the 40 mg dose is initiated.</p><p><strong>Prevention of cardiovascular events</strong></p><p>In the cardiovascular events risk reduction study, the dose used was 20 mg daily (see section&nbsp;5.1).</p><p><strong>Paediatric population</strong></p><p>Paediatric use should only be carried out by specialists.&nbsp;Children and adolescents 10 to 17 years of age (boys Tanner Stage II and above, and girls&nbsp;who are at least 1 year post-menarche)&nbsp;In children and adolescents with heterozygous familial hypercholesterolemia the usual start&nbsp;dose is 5 mg daily. The usual dose range is 5-20 mg orally once daily. Titration should be&nbsp;conducted according to the individual response and tolerability in paediatric patients, as&nbsp;recommended by the paediatric treatment recommendations (see section 4.4). Children and&nbsp;adolescents should be placed on standard cholesterol-lowering diet before rosuvastatin&nbsp;treatment initiation; this diet&nbsp;should be continued during rosuvastatin treatment. Safety and&nbsp;efficacy of doses greater than 20 mg have not been studied in this population.&nbsp;The 40 mg tablet is not&nbsp;suitable for use in paediatric patients.&nbsp;Children younger than 10 years&nbsp;Experience in children younger than 10 years is limited to a small number of children (aged&nbsp;between 8 and 10 years) with homozygous familial hypercholesterolemia. Therefore,&nbsp;CREVAST is not recommended for use in children younger than 10 years.</p><p><strong>Use in the elderly</strong></p><p>A start dose of 5 mg is recommended in patients &gt;70 years (see section 4.4). No other dose&nbsp;adjustment is necessary in relation to age.</p><p><strong>Dosage in patients with renal insufficiency</strong></p><p>No dose adjustment is necessary in patients with mild to moderate renal impairment.&nbsp;The recommended start dose is 5 mg in patients with moderate renal impairment (creatinine&nbsp;clearance &lt;60 ml/min). The 40 mg dose is contraindicated in patients with moderate renal&nbsp;impairment. The use of CREVAST in patients with severe renal&nbsp;impairment is contraindicated&nbsp;for all doses (see section 4.3 and section 5.2).</p><p><strong>Dosage in patients with hepatic impairment</strong></p><p>There was no increase in systemic exposure to rosuvastatin in subjects with Child-Pugh&nbsp;scores of 7 or below. However, increased systemic exposure has been observed in subjects&nbsp;with Child-Pugh scores of 8 and 9 (see section 5.2). In these patients an assessment of renal&nbsp;function should be considered (see section 4.4). There is no experience in subjects with Child-&nbsp;Pugh scores above 9. CREVAST is contraindicated in patients with active liver disease (see&nbsp;section 4.3).</p><p><strong>Race</strong></p><p>Increased systemic exposure has been seen in Asian subjects (see sections4.3, 4.4 and 5.2).&nbsp;The recommended start dose is 5 mg for patients of Asian ancestry. The 40 mg dose is&nbsp;contraindicated in these patients.</p><p><strong>Dosage in patients with predisposing factors to myopathy</strong></p><p>The recommended start dose is 5 mg in patients with predisposing factors to myopathy (see&nbsp;section 4.4).&nbsp;The 40 mg dose is contraindicated in some of these patients (see section 4.3).&nbsp;Method of administration&nbsp;CREVAST may be given at any time of day, with or without food.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                CREVAST is contraindicated:
- in patients with hypersensitivity to the active substance or to any of the excipients listed
in section 6.1.
- in patients with active liver disease including unexplained, persistent elevations of
serum transaminases and any serum transaminase elevation exceeding 3 x the upper
limit of normal (ULN).
- in patients with severe renal impairment (creatinine clearance <30 ml/min).
- in patients with myopathy.
- in patients receiving concomitant ciclosporin.
- during pregnancy and lactation and in women of childbearing potential not using
appropriate contraceptive measures.
The 40 mg dose is contraindicated in patients with pre-disposing factors for
myopathy/rhabdomyolysis. Such factors include:
- moderate renal impairment (creatinine clearance < 60 ml/min)
- hypothyroidism
- personal or family history of hereditary muscular disorders
- previous history of muscular toxicity with another HMG-CoA reductase inhibitor or
fibrate
- alcohol abuse
- situations where an increase in plasma levels may occur
- Asian patients
- concomitant use of fibrates.
(See sections 4.4, 4.5 and 5.2).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Renal Effects</u></p><p>Proteinuria, detected by dipstick testing and mostly tubular in origin, has been observed in&nbsp;patients treated with higher doses of rosuvastatin, in particular 40 mg, where it was transient&nbsp;or intermittent in most cases. Proteinuria has not been shown to be predictive of acute or&nbsp;progressive renal disease (see section 4.8). The&nbsp;reporting rate for serious renal events in postmarketing&nbsp;use is higher at the 40 mg dose. An assessment of renal function should be&nbsp;considered during routine follow-up&nbsp;of patients treated with a dose of 40 mg.</p><p><u>Skeletal Muscle Effects</u></p><p>Effects on skeletal muscle e.g. myalgia, myopathy and, rarely, rhabdomyolysis have been&nbsp;reported in rosuvastatin -treated patients with all doses and in particular with doses &gt; 20 mg.&nbsp;Very rare cases of rhabdomyolysis have been reported with the use of ezetimibe in&nbsp;combination with HMG-CoA reductase inhibitors. A pharmacodynamic interaction cannot be&nbsp;excluded (see section 4.5) and caution should be exercised with their combined use.&nbsp;As with other HMG-CoA reductase inhibitors, the reporting rate for rhabdomyolysis&nbsp;associated with rosuvastatin in post-marketing use is higher at the 40 mg dose.</p><p><em>Creatine Kinase Measurement</em></p><p>Creatine Kinase (CK) should not be measured following strenuous exercise or in the presence&nbsp;of a plausible alternative cause of CK increase which may confound interpretation of the&nbsp;result. If CK levels are significantly elevated at baseline (&gt;5xULN) a confirmatory test should&nbsp;be carried out within 5 &ndash; 7 days. If the repeat test&nbsp;confirms a baseline CK &gt;5xULN, treatment&nbsp;should not be started.</p><p><em>Before Treatment</em></p><p>Rosuvastatin, as with other HMG-CoA reductase inhibitors, should be prescribed with caution&nbsp;in patients with pre-disposing factors for myopathy/rhabdomyolysis. Such&nbsp;factors include:</p><p>&bull; renal impairment</p><p>&bull; hypothyroidism</p><p>&bull; personal or family history of hereditary muscular disorders</p><p>&bull; previous history of muscular toxicity with another HMG-CoA reductase inhibitor or</p><p>fibrate</p><p>&bull; alcohol abuse</p><p>&bull; age &gt;70 years</p><p>&bull; situations where an increase in plasma levels may occur (see section 5.2)</p><p>&bull; concomitant use of fibrates.</p><p>In such patients the risk of treatment should be considered in relation to possible benefit and&nbsp;clinical monitoring is recommended. If CK levels are significantly elevated at baseline&nbsp;(&gt;5xULN) treatment should not be started.</p><p><em>Whilst on Treatment</em></p><p>Patients should be asked to report inexplicable muscle pain, weakness or cramps immediately,&nbsp;particularly if associated with malaise or fever. CK levels should be measured in these&nbsp;patients. Therapy should be discontinued if CK levels are markedly elevated (&gt;5xULN) or if&nbsp;muscular symptoms are severe and cause daily discomfort (even if CK levels are &le; 5x ULN).&nbsp;If symptoms resolve and CK levels return to normal, then consideration should be given to reintroducing&nbsp;rosuvastatin or an alternative HMG-CoA reductase inhibitor at the lowest dose&nbsp;with close monitoring. Routine monitoring of CK levels in asymptomatic patients is not&nbsp;warranted.&nbsp;In clinical trials there was no evidence of increased skeletal muscle effects in the small&nbsp;number of patients dosed with rosuvastatin and concomitant therapy. However, an increase in&nbsp;the incidence of myositis and myopathy has been seen in patients receiving other HMG-CoA&nbsp;reductase inhibitors together with fibric acid derivatives including gemfibrozil, ciclosporin,&nbsp;nicotinic acid, azole antifungals, protease inhibitors and macrolide antibiotics. Gemfibrozil&nbsp;increases the risk of myopathy when given concomitantly with some HMG-CoA reductase&nbsp;inhibitors. Therefore, the combination of rosuvastatin and gemfibrozil is not recommended.&nbsp;The benefit of further&nbsp;alterations in lipid levels by the combined use of rosuvastatin with&nbsp;fibrates or niacin should be carefully weighed against the potential risks of such combinations. The 40 mg dose is contraindicated with concomitant use of a fibrate(see section&nbsp;4.5 and section 4.8).</p><p>Rosuvastatin should not be used in any patient with an acute, serious condition suggestive of&nbsp;myopathy or predisposing to the development of renal failure secondary to rhabdomyolysis&nbsp;(e.g. sepsis, hypotension, major surgery, trauma, severe metabolic, endocrine and electrolyte&nbsp;disorders; or uncontrolled seizures).</p><p><u>Liver Effects</u></p><p>As with other HMG-CoA reductase inhibitors, rosuvastatinshould be used with caution in&nbsp;patients who consume excessive quantities of alcohol and/or have a history of liver disease.&nbsp;It is recommended that liver function tests be carried out prior to, and 3 months following, the&nbsp;initiation of treatment. Rosuvastatin should be discontinued or the dose reduced if the level of&nbsp;serum transaminases is greater than 3 times the upper limit of normal. The reporting rate for&nbsp;serious hepatic events (consisting mainly of increased hepatic transaminases) in postmarketing&nbsp;use is higher at the 40 mg dose.</p><p>In patients with secondary caused by hypothyroidism or nephrotic syndrome, the underlyindisease should be treated prior to initiating therapy with rosuvastatin.</p><p><u>Race</u></p><p>Pharmacokinetic studies show an increase in exposure in Asian subjects compared with&nbsp;Caucasians (see sections 4.2, 4.3 and 5.2).</p><p><u>Protease inhibitors</u></p><p>The concomitant use with protease inhibitors is not recommended (see section 4.5).</p><p><u>Lactose intolerance</u></p><p>Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or&nbsp;glucose-galactose malabsorption should not take this medicine.</p><p><u>Interstitial lung disease</u></p><p>&nbsp;</p><p>Exceptional cases of interstitial lung disease have been reported with some statins, especially&nbsp;with long term therapy (see section 4.8). Presenting features can include dyspnoea, nonproductive&nbsp;cough and deterioration in general health (fatigue, weight loss and fever). If it is&nbsp;suspected that a patient has developed interstitial lung disease, statin therapy should be&nbsp;discontinued.</p><p><u>Diabetes Mellitus</u></p><p>Some evidence suggests that statins as a class raise blood glucose and in some patients, at&nbsp;high risk of future diabetes, may produce a level of hyperglycaemia where formal diabetes&nbsp;care is appropriate. This risk, however, is outweighed by the reduction in vascular risk with&nbsp;statins and therefore should not be a reason for stopping statin treatment. Patients at risk of&nbsp;hyperglycaemia (fasting glucose 5.6 to 6.9 mmol/L, BMI&gt;30kg/m2, raised triglycerides,&nbsp;hypertension) should be monitored both&nbsp;clinically and biochemically according to national&nbsp;guidelines.</p><p>In the JUPITER study, the reported overall frequency of diabetes mellitus was 2.8% in&nbsp;rosuvastatin and 2.3% in placebo, mostly in patients with fasting glucose 5.6 to 6.9 mmol/L.</p><p><u>Paediatric population</u>&nbsp;</p><p>The evaluation of linear growth (height), weight, BMI (body mass index), and secondary&nbsp;characteristics of sexual maturation by Tanner staging in paediatric patients 10 to 17 years of&nbsp;age taking rosuvastatin is limited to a one-year period. After 52 weeks of study treatment, no&nbsp;effect on growth, weight, BMI or sexual maturation was detected (see section 5.1). The&nbsp;clinical trial experience in children and adolescent patients is limited and the long-term effects&nbsp;of rosuvastatin (&gt;1 year) on puberty are unknown.&nbsp;In a clinical trial of children and adolescents receiving rosuvastatin for 52 weeks, CK&nbsp;elevations &gt;10xULN and muscle symptoms following exercise or increased physical activity&nbsp;were observed more frequently compared to observations in clinical trials in adults (seesection 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Ciclosporin</strong>: During concomitant treatment with rosuvastatin and ciclosporin, rosuvastatin</p><p>AUC values were on average 7 times higher than those observed in healthy volunteers (see</p><p>section 4.3).</p><p>Concomitant administration did not affect plasma concentrations of ciclosporin.</p><p><strong>Vitamin K antagonists:</strong>&nbsp;As with other HMG-CoA reductase inhibitors, the initiation of&nbsp;treatment or dosage up-titration of rosuvastatin in patients treated concomitantly with vitamin&nbsp;K antagonists (e.g. warfarin or another coumarin anticoagulant) may result in an increase in&nbsp;International Normalised Ratio (INR). Discontinuation or down-titration of rosuvastatin may&nbsp;result in a decrease in INR. In such situations, appropriate monitoring of INR is desirable.</p><p><strong>Ezetimibe</strong>: Concomitant use of rosuvastatin and ezetimibe resulted in no change to AUC or&nbsp;Cmaxfor either drug. However, a pharmacodynamic interaction, in terms of adverse effects,&nbsp;between rosuvastatin and ezetimibe cannot be ruled out (see section 4.4).</p><p><strong>Gemfibrozil and other lipid-lowering products:&nbsp;</strong>Concomitant use of rosuvastatin and&nbsp;gemfibrozil resulted in a 2-fold increase in rosuvastatin Cmax and AUC (see section 4.4).&nbsp;Based on data from specific interaction studies no pharmacokinetic relevant interaction with&nbsp;fenofibrate is expected, however a pharmacodynamic interaction may occur. Gemfibrozil,&nbsp;fenofibrate, other fibrates and lipid lowering doses (&gt; or equal to 1g/day) of niacin (nicotinic acid) increase the risk of myopathy&nbsp;when given concomitantly with HMG-CoA reductase&nbsp;inhibitors, probably because they can produce myopathy when given alone. The 40 mg dose is&nbsp;contraindicated with&nbsp;concomitant use of a fibrate (see section 4.3 and section 4.4). These&nbsp;patients should also start with the 5 mg dose.</p><p><strong>Protease inhibitors:&nbsp;</strong>Although the exact mechanism of interaction is unknown, concomitant&nbsp;protease inhibitor use may strongly increase rosuvastatin exposure. In a pharmacokinetic&nbsp;study, co-administration of 20 mg rosuvastatin and a combination product of two protease&nbsp;inhibitors (400 mg lopinavir / 100 mg ritonavir) in healthy volunteers was associated with an&nbsp;approximately two-fold and five-fold increase in rosuvastatin steady-state AUC(0-24)and Cmax&nbsp;respectively. Therefore, concomitant use of rosuvastatin in HIV patients receiving protease&nbsp;inhibitors is not recommended (see also section 4.4).</p><p><strong>Antacid:</strong>&nbsp;The simultaneous dosing of rosuvastatin with an antacid suspension containing&nbsp;aluminium and magnesium hydroxide resulted in a decrease in rosuvastatin plasma&nbsp;concentration of approximately 50%. This effect was mitigated when the antacid was dosed 2&nbsp;hours after rosuvastatin. The clinical relevance of this interaction&nbsp;has not been studied.</p><p><strong>Erythromycin:</strong>&nbsp;Concomitant use of rosuvastatin and erythromycin resulted in a 20% decrease&nbsp;in AUC(0-t) and a 30% decrease in Cmaxof rosuvastatin. This interaction may be caused by the&nbsp;increase in gut motility caused by erythromycin.</p><p><strong>Oral contraceptive/hormone replacement therapy (HRT):</strong>&nbsp;Concomitant use of&nbsp;rosuvastatin and an oral contraceptive resulted in an increase in ethinyl estradiol and&nbsp;norgestrel AUC of 26% and 34%, respectively. These increased plasma levels should be&nbsp;considered when selecting oral contraceptive doses. There are no pharmacokinetic data&nbsp;available in subjects taking concomitant rosuvastatin and HRT and therefore a similar effect&nbsp;cannot be excluded. However, the combination has been extensively used in women in&nbsp;clinical trials and was well tolerated.</p><p><strong>Other medicinal products:</strong>&nbsp;Based on data from specific interaction studies no clinically&nbsp;relevant interaction with digoxin is expected.</p><p><strong>Cytochrome P450 enzymes:&nbsp;</strong>Results from in vitro and in vivo studies show that rosuvastatin&nbsp;is neither an inhibitor nor an inducer of cytochrome P450 isoenzymes. In addition,&nbsp;rosuvastatin is a poor substrate for these isoenzymes. No clinically relevant interactions have&nbsp;been observed between rosuvastatin and either fluconazole (an inhibitor of CYP2C9 and&nbsp;CYP3A4) or ketoconazole (an inhibitor of CYP2A6 and CYP3A4). Concomitant&nbsp;administration of itraconazole (an inhibitor of CYP3A4) and rosuvastatin resulted in a 28%&nbsp;increase in AUC of rosuvastatin. This small increase is not considered clinically significant.&nbsp;Therefore, drug interactions resulting from&nbsp;cytochrome P450-mediated metabolism are not&nbsp;expected.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Rosuvastatin is pregnancy category X.</p><p>Rosuvastatin is contraindicated in pregnancy and lactation.&nbsp;Women of child bearing potential should use appropriate contraceptive measures.</p><p>Since cholesterol and other products of cholesterol biosynthesis are essential for the development of the foetus, the potential risk from inhibition of HMG-CoA reductase&nbsp;outweighs the advantage of treatment during pregnancy. Animal studies provide limited evidence of reproductive toxicity (see section 5.3). If a patient becomes pregnant during use of this product, treatment should be discontinued immediately.</p><p>Rosuvastatin is excreted in the milk of rats. There are no data with respect to excretion in milk in humans(see section 4.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Studies to determine the effect of rosuvastatin on the ability to drive and use machines have &nbsp; not been conducted. However, based on its pharmacodynamic properties, rosuvastatin is unlikely to affect this ability. When driving vehicles or operating machines, it should be taken into account that dizziness may occur during treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The adverse reactions seen with rosuvastatin are generally mild and transient. In controlled clinical trials, less than 4% of rosuvastatin -treated patients were withdrawn due to adverse reactions.</p><p>&nbsp;</p><p>Tabulated list of adverse reactions</p><p>Based on data from clinical studies and extensive post-marketing experience, the following table presents the adverse reaction profile for rosuvastatin. Adverse reactions listed below are classified according to frequency and system organ class (SOC).</p><p>The frequencies of adverse reactions are ranked according to the following convention:&nbsp;</p><p>Common (&ge;1/100 to&lt;1/10);</p><p>Uncommon (&ge;1/1,000 to&lt;1/100);&nbsp;</p><p>Rare (&ge;1/10,000 to&lt;1/1000);&nbsp;</p><p>Very rare (&lt;1/10,000);</p><p>Not known (cannot be estimated from the available data).</p><p><strong>Table 1.Adverse reactions based on data from clinical studies and post-marketing</strong></p><p><strong>experience</strong></p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td><p><strong>System organ class</strong></p></td><td><p><strong>Common</strong></p></td><td><p><strong>Uncommon</strong></p></td><td><p><strong>Rare</strong></p></td><td><p><strong>Very rare</strong></p></td><td><p><strong>Not&nbsp;known</strong></p></td></tr><tr><td><p>Blood and</p><p>lymphatic system</p><p>disorders</p></td><td>&nbsp;</td><td>&nbsp;</td><td><p>Thrombocytopenia</p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>Immune system</p><p>disorders</p></td><td>&nbsp;</td><td>&nbsp;</td><td><p>Hypersensitivity&nbsp;reactions</p><p>including&nbsp;angioedema</p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>Endocrine</p><p>disorders</p></td><td><p>Diabetes&nbsp;mellitus</p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>Psychiatric</p><p>disorders</p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td><p>Depression</p></td></tr><tr><td><p>Nervous system</p><p>disorders</p></td><td><p>Headache</p><p>Dizziness</p></td><td>&nbsp;</td><td>&nbsp;</td><td><p>Polyneuropathy Memory&nbsp;loss</p></td><td><p>Sleep&nbsp;disturbances</p><p>(including&nbsp;insomnia&nbsp;and&nbsp;nightmares)</p></td></tr><tr><td><p>Respiratory,</p><p>thoracic and</p><p>mediastinal</p><p>disorders</p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td><p>Cough&nbsp;Dyspnoea</p></td></tr><tr><td><p>Gastrointestinal</p><p>disorders</p></td><td><p>Constipation Nausea</p><p>Abdominal&nbsp;pain</p></td><td>&nbsp;</td><td><p>Pancreatitis</p></td><td>&nbsp;</td><td><p>Diarrhoea</p></td></tr><tr><td><p>Hepatobiliary</p><p>disorders</p></td><td>&nbsp;</td><td>&nbsp;</td><td><p>Increased&nbsp;hepatic&nbsp;transaminases</p></td><td><p>Jaundice</p><p>Hepatitis</p></td><td>&nbsp;</td></tr><tr><td><p>Skin and</p><p>subcutaneous</p><p>tissue</p><p>disorders</p></td><td>&nbsp;</td><td><p>Pruritis&nbsp;Rash&nbsp;Urticaria</p></td><td>&nbsp;</td><td>&nbsp;</td><td><p>Stevens-&nbsp;Johnson&nbsp;syndrome</p></td></tr><tr><td><p>Musculoskeletal</p><p>and connective</p><p>tissue disorders</p></td><td><p>Myalgia</p></td><td>&nbsp;</td><td><p>Myopathy</p><p>(including&nbsp;myositis)</p><p>Rhabdomyolysis</p></td><td><p>Arthralgia</p></td><td>&nbsp;</td></tr><tr><td><p>Renal and urinary</p><p>disorders</p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td><p>Haematuria</p></td><td>&nbsp;</td></tr><tr><td><p>Reproductive</p><p>system and breast</p><p>disorders</p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td><p>Gynaecomastia</p></td><td>&nbsp;</td></tr><tr><td><p>General disorders</p><p>and administration</p><p>site conditions</p></td><td><p>Asthenia</p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td><p>Oedema</p></td></tr><tr><td colspan="6"><p><sup>1</sup>&nbsp;Frequency will depend on the presence or absence of risk factors (fasting blood glucose</p><p>&ge; 5,6 mmol/L, BMI &gt;30 kg/m<sup>2</sup>, raised triglycerides, history of hypertension)</p></td></tr></tbody></table><p>As with other HMG-CoA reductase inhibitors, the incidence of adverse drug reactions tends</p><p>to be dose dependent.</p><p><strong>Renal Effects:</strong>&nbsp;Proteinuria, detected by dipstick testing and mostly tubular in origin, has been</p><p>observed in patients treated with rosuvastatin. Shifts in urine protein from none or trace to ++</p><p>or more were seen in &lt;1% of patients at some time during treatment with 10 and 20 mg, and</p><p>in approximately 3% of patients treated with 40 mg. A minor increase in shift from none or</p><p>trace to + was observed with the 20 mg dose. In most cases, proteinuria decreases or</p><p>disappears spontaneously on continued therapy. Review of data from clinical trials and postmarketing</p><p>experience to date has not identified a causal association between proteinuria and</p><p>acute or progressive renal disease.</p><p>Haematuria has been observed in patients treated with rosuvastatin and clinical trial data show</p><p>that the occurrence is low.</p><p><strong>Skeletal muscle effects:</strong>&nbsp;Effects on skeletal muscle e.g.myalgia, myopathy (including</p><p>myositis) and, rarely, rhabdomyolysis with and without acute renal failure have been reported</p><p>in rosuvastatin -treated patients with all doses and in particular with doses &gt; 20 mg.</p><p>A dose-related increase in CK levels has been observed inpatients taking rosuvastatin; the</p><p>majority of cases were mild, asymptomatic and transient. If CK levels are elevated</p><p>(&gt;5xULN), treatment should be discontinued (see section 4.4).</p><p><strong>Liver Effects:</strong>&nbsp;As with other HMG-CoA reductase inhibitors, a dose-related increase in</p><p>transaminases has been observed in a small number of patients taking rosuvastatin; the</p><p>majority of cases were mild, asymptomatic and transient.</p><p><strong>The following adverse events have been reported with some statins:</strong></p><p>- Sexual dysfunction,</p><p>- Exceptional cases of interstitial lung disease, especially with long term therapy (see</p><p>section 4.4),</p><p>- Tendon disorders, sometimes complicated by rupture.</p><p>The reporting rates for rhabdomyolysis, serious renal events and serious hepatic events</p><p>(consisting mainly of increased hepatic transaminases) is higher at the 40 mg dose.</p><p><strong>Paediatric population:&nbsp;</strong>Creatine kinase elevations &gt;10xULN and muscle symptoms</p><p>following exercise or increased physical activity were observed more frequently in a 52-week</p><p>clinical trial of children and adolescents compared to adults (see section 4.4). In other</p><p>respects, the safety profile of rosuvastatin was similar in children and adolescents compared</p><p>to adults.</p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td><p>To report any side effect(s):</p><p> The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o Toll free phone: 8002490000</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no specific treatment in the event of overdose. In the event of overdose, the patient&nbsp;should be treated symptomatically and supportive measures instituted as required. Liver&nbsp;function and CK levels should be monitored. Haemodialysis is unlikely to be of benefit.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Lipid modifying agent, plain; HMG-CoA reductase inhibitors&nbsp;ATC code: C10A A07</p><p><u>Mechanism of action</u></p><p>Rosuvastatin is a selective and competitive inhibitor of HMG-CoA reductase, the rate-limiting&nbsp;enzyme that converts 3-hydroxy-3-methylglutaryl coenzyme A to mevalonate, a precursor for &nbsp;cholesterol. The primary site of action of rosuvastatin is the liver, the target organ for</p><p>cholesterol lowering.</p><p>Rosuvastatin increases the number of hepatic LDL receptors on the cell-surface, enhancing&nbsp;uptake and catabolism of LDL and it inhibits the hepatic synthesis of VLDL, thereby reducing&nbsp;the total number of VLDL and LDL particles.</p><p><u>Pharmacodynamic effects&nbsp;</u></p><p>Rosuvastatin reduces elevated LDL-cholesterol, total cholesterol and triglycerides and</p><p>increases HDL-cholesterol. It also lowers ApoB, nonHDL-C, VLDL-C, VLDL-TG and</p><p>increases ApoA-I (see Table 2).&nbsp;</p><p>Rosuvastatin also lowers the LDL-C/HDL-C, total C/HDL-C&nbsp;and nonHDL-C/HDL-C and the ApoB/ApoA-I ratios.</p><p><strong>Table 2 Dose response in patients with primary (type IIa and IIb) (adjusted</strong></p><p><strong>mean percent change from baseline)</strong></p><p>&nbsp;</p><p>&nbsp;</p><table cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Dose</strong></p></td><td><p><strong>N</strong></p></td><td><p><strong>LDL- C</strong></p></td><td><p><strong>Total- C</strong></p></td><td><p><strong>HDL- C</strong></p></td><td><p><strong>TG</strong></p></td><td><p><strong>nonHDL- C</strong></p></td><td><p><strong>ApoB</strong></p></td><td><p><strong>ApoA-I</strong></p></td></tr><tr><td><p>Placebo</p></td><td><p>13</p></td><td><p>-7</p></td><td><p>-5</p></td><td><p>3</p></td><td><p>-3</p></td><td><p>-7</p></td><td><p>-3</p></td><td><p>0</p></td></tr><tr><td><p>5</p></td><td><p>17</p></td><td><p>-45</p></td><td><p>-33</p></td><td><p>13</p></td><td><p>-35</p></td><td><p>-44</p></td><td><p>-38</p></td><td><p>4</p></td></tr><tr><td><p>10</p></td><td><p>17</p></td><td><p>-52</p></td><td><p>-36</p></td><td><p>14</p></td><td><p>-10</p></td><td><p>-48</p></td><td><p>-42</p></td><td><p>4</p></td></tr><tr><td><p>20</p></td><td><p>17</p></td><td><p>-55</p></td><td><p>-40</p></td><td><p>8</p></td><td><p>-23</p></td><td><p>-51</p></td><td><p>-46</p></td><td><p>5</p></td></tr><tr><td><p>40</p></td><td><p>18</p></td><td><p>-63</p></td><td><p>-46</p></td><td><p>10</p></td><td><p>-28</p></td><td><p>-60</p></td><td><p>-54</p></td><td><p>0</p></td></tr></tbody></table><p>&nbsp;</p><p>A therapeutic effect is obtained within 1 week following treatment initiation and 90% of</p><p>maximum response is achieved in 2 weeks. The maximum response is usually achieved by 4</p><p>weeks and is maintained after that.</p><p><u>Clinical efficacy and safety</u></p><p>Rosuvastatin is effective in adults with , with and without hypertriglyceridaemia, regardless of</p><p>race, sex, or age and in special populations such as diabetics, or patients with familial .</p><p>From pooled phase III data, rosuvastatin has been shown to be effective at treating the</p><p>majority of patients with type IIa and IIb (mean baseline LDL-C about 4.8 mmol/l) to</p><p>recognised European Atherosclerosis Society (EAS; 1998) guideline targets; about 80% of</p><p>patients treated with 10 mg reached the EAS targets for LDL-C levels (&lt;3 mmol/l).</p><p>In a large study, 435 patients with heterozygous familial were given rosuvastatin from 20 mg</p><p>to 80 mg in a force-titration design. All doses showed a beneficial effect on lipid parameters</p><p>and treatment to target goals. Following titration to a daily dose of 40 mg (12 weeks of</p><p>treatment), LDL-C was reduced by 53%. 33% of patients reached EAS guidelines for LDL-C</p><p>levels (&lt;3 mmol/l).</p><p>In a force-titration, open label trial, 42 patients with homozygous familial were evaluated for</p><p>their response to rosuvastatin 20 - 40 mg. In the overall population, the mean LDL-C</p><p>reduction was 22%.</p><p>In clinical studies with a limited number of patients, rosuvastatin has been shown to have</p><p>additive efficacy in lowering triglycerides when used in combination with fenofibrate and in</p><p>increasing HDL-C levels when used in combination with niacin (see section 4.4).</p><p>In a multi-centre, double-blind, placebo-controlled clinical study (METEOR), 984 patients</p><p>between 45 and 70 years of age and at low risk for coronary heart disease (defined as</p><p>Framingham risk &lt;10% over 10 years), with a mean LDL-C of 4.0 mmol/l (154.5 mg/dL), but</p><p>with subclinical atherosclerosis (detected by Carotid Intima Media Thickness) were</p><p>randomised to 40 mg rosuvastatin once daily or placebo for 2 years. Rosuvastatin</p><p>significantly slowed the rate of progression of the maximum CIMT for the 12 carotid artery</p><p>sites compared to placebo by -0.0145 mm/year [95% confidence interval -0.0196, -</p><p>0.0093;p&lt;0.0001]. The change from baseline was -0.0014 mm/year (-0.12%/year (nonsignificant))</p><p>for rosuvastatin compared to a progression of +0.0131 mm/year (1.12%/year</p><p>(p&lt;0.0001)) for placebo. No direct correlation between CIMT decrease and reduction of the</p><p>risk of cardiovascular events has yet been demonstrated. The population studied in METEOR</p><p>is low risk for coronary heart disease and does not represent the target population of</p><p>rosuvastatin 40 mg. The 40 mg dose should only be prescribed in patients with severe at high</p><p>cardiovascular risk (see section 4.2).</p><p>In the Justification for the Use of Statins in Primary Prevention: An Intervention Trial</p><p>Evaluating Rosuvastatin (JUPITER) study, the effect of rosuvastatin on the occurrence of</p><p>major atherosclerotic cardiovascular disease events was assessed in 17,802 men (&ge;50 years)</p><p>and women (&ge;60 years).</p><p>Study participants were randomly assigned to placebo (n=8901) or rosuvastatin 20 mg once</p><p>daily (n=8901) and were followed for a mean duration of 2 years.</p><p>LDL-cholesterol concentration was reduced by 45% (p&lt;0.001) in the rosuvastatin group</p><p>compared to the placebo group.</p><p>In a post-hoc analysis of a high-risk subgroup of subjects with a baseline Framingham risk</p><p>score &gt;20% (1558 subjects) there was a significant reduction in the combined end-point of</p><p>cardiovascular death, stroke and myocardial infarction (p=0.028) on rosuvastatin treatment</p><p>versus placebo. The absolute risk reduction in the event rate per 1000 patient-years was 8.8.</p><p>Total mortality was unchanged in this high risk group (p=0.193). In a post-hoc analysis of a</p><p>high-risk subgroup of subjects (9302 subjects total) with a baseline SCORE risk &ge;5%</p><p>(extrapolated to include subjects above 65 years) there was a significant reduction in the</p><p>combined end-point of cardiovascular death, stroke and myocardial infarction (p=0.0003) on</p><p>rosuvastatin treatment versus placebo. The absolute risk reduction in the event rate was 5.1</p><p>per 1000 patient-years. Total mortality was unchanged in this high risk group (p=0.076).</p><p>In the JUPITER trial there were 6.6% of rosuvastatin and 6.2% of placebo subjects who</p><p>discontinued use of study medication due to an adverse event. The most common adverse</p><p>events that led to treatment discontinuation were: myalgia (0.3% rosuvastatin, 0.2% placebo),</p><p>abdominal pain (0.03% rosuvastatin, 0.02% placebo) and rash (0.02% rosuvastatin, 0.03%</p><p>placebo). The most common adverse events at a rate greater than or equal to placebo were</p><p>urinary tract infection (8.7% rosuvastatin, 8.6% placebo), nasopharyngitis (7.6% rosuvastatin,</p><p>7.2% placebo), back pain (7.6% rosuvastatin, 6.9% placebo) and myalgia (7.6% rosuvastatin,</p><p>6.6% placebo).</p><p><u>Paediatric population</u></p><p>In a double-blind, randomized, multi-centre, placebo-controlled, 12-week study (n=176, 97</p><p>male and 79 female) followed by a 40-week (n=173, 96 male and 77 female), open-label,</p><p>rosuvastatin dose-titration phase, patients 10-17 years of age (Tanner stage II-V, females at</p><p>least 1 year post-menarche) with heterozygous familial received rosuvastatin 5, 10 or 20 mg</p><p>or placebo daily for 12 weeks and then all received rosuvastatin daily for 40 weeks. At study&nbsp;</p><p>entry, approximately 30% of the patients were 10-13 years and approximately 17%, 18%,</p><p>40%, and 25% were Tanner stage II, III, IV, and V, respectively.</p><p>LDL-C was reduced 38.3%, 44.6%, and 50.0% by rosuvastatin 5, 10 and 20 mg, respectively,</p><p>compared to 0.7% for placebo.</p><p>At the end of the 40-week, open-label, titration to goal, dosing up to a maximum of 20 mg</p><p>once daily, 70 of 173 patients (40.5%) had achieved the LDL-C goal of less than 2.8 mmol/l.</p><p>After 52 weeks of study treatment, no effect on growth, weight, BMI or sexual maturation</p><p>was detected (see section 4.4). The clinical trial experience in children and adolescent patients</p><p>is limited and the long-term effects of rosuvastatin (&gt;1 year) on puberty are unknown. This</p><p>trial (n=176) was not suited for comparison of rare adverse drug events.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Maximum rosuvastatin plasma concentrations are achieved approximately 5 hours after oral</p><p>administration. The absolute bioavailability is approximately 20%.</p><p>Distribution</p><p>Rosuvastatin is taken up extensively by the liver which is the primary site of cholesterol</p><p>synthesis and LDL-C clearance. The volume of distribution of rosuvastatin is approximately</p><p>134 L. Approximately 90% of rosuvastatin is bound to plasma proteins, mainly to albumin.</p><p><u>Biotransformation</u></p><p>Rosuvastatin undergoes limited metabolism (approximately 10%). In vitro metabolism studies</p><p>using human hepatocytes indicate that rosuvastatin is a poor substrate for cytochrome P450-</p><p>based metabolism. CYP2C9 was the principal isoenzyme involved, with 2C19, 3A4 and 2D6</p><p>involved to a lesser extent. The main metabolites identified are the N-desmethyl and lactone</p><p>metabolites. The N-desmethyl metabolite is approximately 50% less active than rosuvastatin</p><p>whereas the lactone form is considered clinically inactive. Rosuvastatin accounts for greater</p><p>than 90% of the circulating HMG-CoA reductase inhibitor activity.</p><p><u>Elimination</u></p><p>Approximately 90% of the rosuvastatin dose is excreted unchanged in the faeces (consisting</p><p>of absorbed and non-absorbed active substance) and the remaining part is excreted in urine.</p><p>Approximately 5% is excreted unchanged in urine. The plasma elimination half-life is</p><p>approximately 19 hours. The elimination half-life does not increase at higher doses. The</p><p>geometric mean plasma clearance is approximately 50 litres/hour (coefficient of variation</p><p>21.7%). As with other HMG-CoA reductase inhibitors, the hepatic uptake of rosuvastatin</p><p>involves the membrane transporter OATP-C. This transporter is important in the hepatic</p><p>elimination of rosuvastatin.</p><p><u>Linearity</u></p><p>Systemic exposure of rosuvastatin increases in proportion to dose. There are no changes in</p><p>pharmacokinetic parameters following multiple daily doses.</p><p>&nbsp;</p><p><strong>Special populations:</strong></p><p>Age and sex: There was no clinically relevant effect of age or sex on the pharmacokinetics of</p><p>rosuvastatin. The pharmacokinetics of rosuvastatin in children and adolescents with &nbsp;heterozygous familial was similar to that of adult volunteers (see &ldquo;Paediatric population&rdquo;</p><p>below).</p><p><strong>Race:&nbsp;</strong>Pharmacokinetic studies show an approximate 2-fold elevation in median AUC and</p><p>Cmax in Asian subjects (Japanese, Chinese, Filipino, Vietnamese and Koreans) compared with</p><p>Caucasians; Asian-Indians show an approximate 1.3-fold elevation in median AUC and Cmax.</p><p>A population pharmacokinetic analysis revealed no clinically relevant differences in</p><p>pharmacokinetics between Caucasian and Black groups.</p><p><strong>Renal insufficiency:&nbsp;</strong>In a study in subjects with varying degrees of renal impairment, mild to</p><p>moderate renal disease had no influence on plasma concentration of rosuvastatin or the Ndesmethyl</p><p>metabolite. Subjects with severe impairment (CrCl &lt;30 ml/min) had a 3-fold</p><p>increase in plasma concentration and a 9-fold increase in the N-desmethyl metabolite</p><p>concentration compared to healthy volunteers. Steady-state plasma concentrations of</p><p>rosuvastatin in subjects undergoing haemodialysis were approximately 50% greater compared</p><p>to healthy volunteers.</p><p><strong>Hepatic insufficiency:</strong>&nbsp;In a study with subjects with varying degrees of hepatic impairment</p><p>there was no evidence of increased exposure to rosuvastatin in subjects with Child-Pugh</p><p>scores of 7 or below. However, two subjects with Child-Pugh scores of 8 and 9 showed an</p><p>increase in systemic exposure of at least 2-fold compared to subjects with lower Child-Pugh</p><p>scores. There is no experience in subjects with Child-Pugh scores above 9.</p><p><strong>Paediatric population:&nbsp;</strong>The pharmacokinetic parameters in paediatric patients with</p><p>heterozygous familial aged 10 to 17 years have not been fully characterised. A small</p><p>pharmacokinetic study with rosuvastatin (given as tablets) in 18 paediatric patients</p><p>demonstrated that exposure in paediatric patients appears comparable to exposure in adult</p><p>patients. In addition, the results indicate that a large deviation from dose proportionality is not</p><p>expected.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data reveal no special hazard for humans based on conventional studies of safety</p><p>pharmacology, genotoxicity and carcinogenicity potential. Specific tests for effects on hERG</p><p>have not been evaluated. Adverse reactions not observed in clinical studies, but seen in</p><p>animals at exposure levels similar to clinical exposure levels were as follows: In repeateddose</p><p>toxicity studies histopathologic liver changes likely due to the pharmacologic action of</p><p>rosuvastatin were observed in mouse, rat, and to a lesser extent with effects in the gall bladder</p><p>in dogs, but not in monkeys. In addition, testicular toxicity was observed in monkeys and</p><p>dogs at higher dosages. Reproductive toxicity was evident in rats, with reduced litter sizes,</p><p>litter weight and pup survival observed at maternally toxic doses, where systemic exposures</p><p>were several times above the therapeutic exposure level.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tablet core</p><p>Microcrystalline cellulose</p><p>Crospovidone type A</p><p>Calcium hydrogen phosphate dihydrate&nbsp;</p><p>Lactose monohydrate</p><p>Magnesium stearate</p><p>Tablet coat</p><p>Hypromellose</p><p>Titanium dioxide (E171)</p><p>Lactose monohydrate</p><p>Macrogol 3350</p><p>Triacetin</p><p>Carmine (E120) (10 mg, 20 mg and 40 mg tablets)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product does not require any special storage conditions.</p><p>Do not store above 30&ordm; C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Blister PVC/PVDC-Al and Al-Al and OPA/AL/PVC Blister : 30 tablets</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p><p>Any unused product or waste should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SPIMACO
Al-Qassim pharmaceutical plant
Saudi Pharmaceutical Industries &
Medical Appliance Corporation
Saudi Arabia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                July 2017
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>